SCHEMBL1248607

SCHEMBL1248607

CCOC(=O)/C=C(\C)C=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.54
HCAR2 Q8TDS4 1/20 0.45
ALDH1A1 P00352 5/20 0.44
LMNA P02545 2/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 4/20 0.41
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
ATM Q13315 1/20 0.40
GLO1 Q04760 1/20 0.39
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1248610 1.00 NPSR1 (0.54) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL7552831 1.00 NPSR1 (0.54) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL11168141 0.83 NPSR1 (0.43) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL8778884 0.83 NPSR1 (0.43) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL8778882 0.83 NPSR1 (0.43) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL10959675 0.83 NPSR1 (0.43) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL9666690 0.83 NPSR1 (0.43) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL6023236 0.80 NPSR1 (0.52) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL6023238 0.80 NPSR1 (0.52) NPSR1HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL9517913 0.79 ATM (0.59) NPSR1HCAR2ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615879-B1 PROCESS FOR THE PRODUCTION OF 9-CIS RETINOIC ACID GLAXO GROUP LTD (GB) 2014-01-29 EP claimed
CN-1323071-C Process for the production of 9-cis retinoic acid. HOFFMANN LA ROCHE (CH) 2007-06-27 CN claimed
CN-1771227-A Process for the production of 9-cis retinoic acid. HOFFMANN LA ROCHE (CH) 2006-05-10 CN claimed
US-7015353-B2 Process for the production of 9-(Z)-retinoic acid HOFFMANN-LA ROCHE INC. (US) 2006-03-21 US claimed
EP-1615879-A1 PROCESS FOR THE PRODUCTION OF 9-CIS RETINOIC ACID F. HOFFMANN-LA ROCHE AG (CH) 2006-01-18 EP claimed
US-20040235951-A1 Process for the production of 9-(Z)-retinoic acid BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) 2004-11-25 US claimed
WO-2004089887-A1 PROCESS FOR THE PRODUCTION OF 9-CIS RETINOIC ACID F. HOFFMANN-LA ROCHE AG (CH) 2004-10-21 WO claimed
EP-0371264-A2 Phosphonate reagent compositions and methods of making same LOYOLA UNIVERSITY OF CHICAGO (US) 1990-06-06 EP claimed
WO-2024006776-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF RELAY THERAPEUTICS, INC. (US) 2024-01-04 WO disclosed
CN-117098749-A [11C] Labeled acyclic retinoids, central nervous system activators and methods for their manufacture 国立研究开发法人国立长寿医疗研究中心 2023-11-21 CN disclosed
WO-2022107865-A1 [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME 国立研究開発法人国立長寿医療研究センター 2022-05-27 WO disclosed
CN-112898147-B Method for asymmetric synthesis of (13R,14S) -13-hydroxy-14-methylhexadecanoic acid 中国农业大学 2022-02-11 CN disclosed
US-11116212-B2 Carbonyl containing compounds for controlling and repelling Cimicidae populations SEMIOSBIO TECHNOLOGIES INC. (CA) 2021-09-14 US disclosed
US-8889660-B2 Methods for treating obesity or an obesity related condition CASE WESTERN RESERVE UNIVERSITY (US) 2014-11-18 US disclosed
US-5296505-A Reacting dithianepropenol with ethynyl-beta-ionol in presence of organomagnesium compound, hydrogenating triple bond, reducing diol with low-valency titanium L'OREAL (FR) 1994-03-22 US disclosed
US-5061819-A Methods for synthesizing phosphonate reagents and retinoids LOYOLA UNIVERSITY OF CHICAGO (US) 1991-10-29 US disclosed
EP-0371264-A2 Phosphonate reagent compositions and methods of making same LOYOLA UNIVERSITY OF CHICAGO (US) 1990-06-06 EP disclosed
US-4916250-A Phosphonate reagent compositions LOYOLA UNIVERSITY OF CHICAGO (US) 1990-04-10 US disclosed
EP-0010208-B1 PHARMACEUTICAL COMPOSITION CONTAINING ALL-E- OR 13-Z-7,8-DEHYDRO-RETINOIC ACID AND PROCESS FOR ITS PREPARATION BASF Aktiengesellschaft (DE) 1982-08-11 EP disclosed
EP-0010208-A1 Pharmaceutical composition containing all-E- or 13-Z-7,8-dehydro-retinoic acid and process for its preparation BASF Aktiengesellschaft (DE) 1980-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235951-A1 Process for the production of 9-(Z)-retinoic acid RARA, RARB, RARG NPSR1 4545/4885HCAR2 1132/4885ALDH1A1 1043/4885
US-11116212-B2 Carbonyl containing compounds for controlling and repelling Cimicidae populations DDT, AOC1, EGLN1 NPSR1 3408/4885HCAR2 2072/4885ALDH1A1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.